High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention (FACT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Ottawa Hospital Research Institute
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01355159
First received: May 11, 2011
Last updated: May 12, 2014
Last verified: May 2014
  Purpose

The hypothesis of the study is: high dose (4.0 mg per day) supplementation for pregnant women at high risk of developing preeclampsia starting in early pregnancy and continued throughout the entire pregnancy will lower the incidence of preeclampsia.


Condition Intervention Phase
Pregnancy Complications
Preeclampsia
Drug: Folic Acid 4 mg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT)

Resource links provided by NLM:


Further study details as provided by Ottawa Hospital Research Institute:

Primary Outcome Measures:
  • Preeclampsia [ Time Frame: Participants will be followed from 20+0 weeks of gestational age until 42 days postpartum (after delivery) ] [ Designated as safety issue: No ]

    PE is defined as diastolic blood pressure ≥90 mmHg on two occasions ≥4 hours apart and proteinuria developed in women greater than 20+0 weeks of gestation.

    Or HELLP (Haemolysis, Elevated, Liver Enzymes, Low Platelets) syndrome Or Superimposed pre-eclampsia, defined as history of pre-existing hypertension (diagnosed pre-pregnancy or before 20+0 weeks' gestation) with new proteinuria.



Secondary Outcome Measures:
  • Maternal death [ Time Frame: Participants will be followed from randomization until 42 days postpartum (after delivery) ] [ Designated as safety issue: No ]
    According to the World Health Organization, "A maternal death is defined as the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.

  • Severe preeclampsia [ Time Frame: Participants will be followed from 20+0 weeks of gestation until 42 days postpartum (after delivery) ] [ Designated as safety issue: No ]
    Severe preeclampsia is defined as preeclampsia with onset before 34+0 weeks gestation, with heavy proteinuria (3-5 g/d) or with one or more adverse conditions which consist of maternal symptoms, maternal signs of end-organ dysfunction, abnormal maternal laboratory testing , or fetal morbidity.

  • Placenta abruptio [ Time Frame: Participants will be followed from 20+0 weeks of gestation until delivery ] [ Designated as safety issue: No ]
    Placental abruption (abruptio placentae) is the premature detachment of a normally positioned placenta from the wall of the uterus.

  • Preterm birth [ Time Frame: Participants will be followed from 20+0 weeks to 36+6 weeks of gestation ] [ Designated as safety issue: No ]
    Birth that occur earlier than 37+0 weeks of gestational age.

  • Premature rupture of membranes [ Time Frame: Participants will be followed from randomization until the onset of labor ] [ Designated as safety issue: No ]
    Rupture of the membranes (rupture of the amniotic sac) before the onset of labor.

  • Antenatal inpatient length of stay [ Time Frame: Participants will be followed from date of randomization until admission for delivery ] [ Designated as safety issue: No ]
    Length of inpatient stay before admission for delivery in days

  • Intrauterine growth restriction [ Time Frame: Participants will be followed from 20+0 weeks of gestation until delivery ] [ Designated as safety issue: No ]
    Intrauterine growth restriction is defined as a birth weight less than the 10th percentile of the population, adjusted for sex and gestational age, based on the current population-based Canadian reference standard.

  • Spontaneous abortion [ Time Frame: Participants will be followed from randomization until 20+0 weeks of gestation ] [ Designated as safety issue: No ]
    Spontaneous abortion or miscarriage defined as death of a fetus <500g or <20 weeks of gestation

  • Perinatal mortality [ Time Frame: Participants will be followed from 20+0 weeks of gestation until 28 days of life ] [ Designated as safety issue: No ]
    The perinatal mortality is defined as the number of deaths (fetal deaths and neonatal deaths) of babies ≥ 500 grams birth weight or, if birth weight is unavailable, a gestational age ≥ 20+0 weeks, up to 28 completed days after birth.

  • Stillbirth [ Time Frame: Participants will be followed from 20+0 weeks of gestation until delivery ] [ Designated as safety issue: No ]
    Fetal death defined as death of fetus of at least 500 grams birth weight or, if birth weight is unavailable, a gestational age of at least 20+0 weeks of gestation.

  • Neonatal death [ Time Frame: Participants will be followed from birth until 28 days of life ] [ Designated as safety issue: No ]
    Neonatal death defined as death of a baby that occurred during first 28 days of life.

  • Retinopathy of prematurity [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 weeks ] [ Designated as safety issue: No ]
    Retinopathy of prematurity a retinopathy typically occurring in premature infants treated with high concentrations of oxygen, characterized by vascular dilatation, proliferation, tortuosity, edema, retinal detachment, and fibrous tissue behind the lens confirmed by retinal examination according to an International Committee for the Classification of Retinopathy of Prematurity.

  • Intraventricular hemorrhage (IVH) [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 weeks ] [ Designated as safety issue: No ]
    • IVH Grade 1(Blood in germinal matrix)
    • IVH Grade 2 (Blood in germinal matrix and extending into the ventricles)
    • IVH Grade 3 (Ventricular enlargement)
    • IVH Grade 4 (Intraparenchymal lesion)

  • Early onset sepsis [ Time Frame: Participants will be followed first 48 hours of life ] [ Designated as safety issue: No ]
    Within first 48hr of life, confirmed by positive blood or cerebrospinal fluid cultures

  • Necrotising enterocolitis [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 weeks ] [ Designated as safety issue: No ]
    Necrotizing enterocolitis (NEC) according to modified Bell's criteria stage 2 or higher (grossly bloody stool, plus absent bowel sounds with or without abdominal tenderness and radiographic findings such as intestinal dilation, ileus, pneumatosis intestinalis), excluding isolated spontaneous intestinal perforations.

  • Ventilation [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 weeks ] [ Designated as safety issue: No ]
    Ventilatory support after initial resuscitation, with/without intubation.

  • Need for oxygen at 28 days [ Time Frame: Participants will be followed for 28 days after birth ] [ Designated as safety issue: No ]
  • Length of stay in 'high level' neonatal care unit [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 6 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 3656
Study Start Date: April 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Folic Acid 4 mg
Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
Drug: Folic Acid 4 mg
Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
Placebo Comparator: Placebo
Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
Drug: Placebo
Placebo x 4 tablets will be taken daily by oral administration.

Detailed Description:

Preeclampsia is a complication of pregnancy which affects at least 5% of all pregnancies worldwide and has serious health consequences to these women and their babies. Preeclampsia is hypertension (high blood pressure) in pregnancy with proteinuria. Proteinuria is when protein is found in the urine, and it is a sign that the kidneys are not functioning properly. The only effective treatment for preeclampsia is delivery of the baby. Because delivery may be required before the anticipated date of delivery; preeclampsia is also one of the leading causes of preterm delivery and accounts for 25% of very low birth weight infants. Recent research has also shown that women who have had preeclampsia during pregnancy are more likely to be at risk for future cardiovascular events later in life.

Recently some studies have shown that supplementation with multivitamins containing folic acid is associated with a reduced risk of developing preeclampsia. These findings also suggested that for the prevention of preeclampsia, a high dose of folic acid (much higher than the amount of folate received from food intake or what is usually taken during pregnancy) may be needed.

Even though the results of these studies showed that folic acid may play role in the prevention of preeclampsia, an additional study is needed to determine conclusively that high dose supplementation of folic acid throughout pregnancy has a preventative effect in pregnant women who are at higher risk than the average pregnant women of developing preeclampsia.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capability of subject to comprehend and comply with study requirements
  2. ≥ 18 years of age at time of consent
  3. Subject is taking ≤1.1 mg of folic acid daily at the time of randomization
  4. Live fetus (documented positive fetal heart prior to randomization)
  5. Gestational age between 8+0 and 16+6 weeks of pregnancy (Gestational age of subjects will be calculated based on the first day of the last menstrual period or ultrasound performed before 12+6. If early ultrasound and LMP dates differ by ≤ 7 days, base GA estimate on LMP date; if > 7 days, use early < 12+6 ultrasound)
  6. Subject plans to give birth in a participating hospital site
  7. Pregnant subjects must fulfill at least one of the following identified risk factors for pre-eclampsia (PE):

    • Pre-existing hypertension (documented evidence of diastolic blood pressure ≥ 90 mmHg on two separate occasions or at least 4 hours apart prior to randomization, or use of antihypertensive medication during this pregnancy specifically for the treatment of hypertension prior to randomization)
    • Pre-pregnancy diabetes (documented evidence of Type I or type II DM)
    • Twin pregnancy
    • Documented evidence of history of PE in a previous pregnancy
    • BMI > 35 kg/m2 within 3 months prior to this pregnancy and up to randomization of this pregnancy (documented evidence of height and weight to calculate BMI is required)

Exclusion Criteria:

  1. Known history or presence of any clinically significant disease or condition which would be a contraindication to folic acid supplementation of up to 5 mg daily for the duration of pregnancy
  2. Known major fetal anomaly or fetal demise
  3. History of medical complications, including:

    • renal disease with altered renal function,
    • epilepsy,
    • cancer, or
    • use of folic acid antagonists such as valproic acid
  4. Individual who is currently enrolled or has participated in another clinical trial or who received an investigational drug within 3 months of the date of randomization (unless approved by the Trial Coordinating Centre)
  5. Known presence of:

    • Alcohol abuse (≥ 2 drinks per day) or alcohol dependence
    • Illicit drug/substance use and/or dependence
  6. Known hypersensitivity to folic acid
  7. Multiple Pregnancy (triplets or more)
  8. Participation in this study in a previous pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01355159

Contacts
Contact: Mark Walker, MD 613-739-6655 mwalker@ohri.ca
Contact: Shi Wu Wen, PhD 613-739-6655 swwen@ohri.ca

Locations
Canada, Ontario
Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Mark C. Walker, MD    613-739-6655    mwalker@ohri.ca   
Principal Investigator: Mark C. Walker, MD         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Shi Wu Wen, PhD Ottawa Hospital Research Institute
Principal Investigator: Mark C Walker, MD Ottawa Hospital Research Institute
  More Information

No publications provided by Ottawa Hospital Research Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT01355159     History of Changes
Other Study ID Numbers: 2009-107, ISRCTN23781770
Study First Received: May 11, 2011
Last Updated: May 12, 2014
Health Authority: Canada: Health Canada
Canada: Ethics Review Committee

Keywords provided by Ottawa Hospital Research Institute:
Pregnancy
Folic Acid supplementation
Preeclampsia

Additional relevant MeSH terms:
Pregnancy Complications
Hypertension, Pregnancy-Induced
Pre-Eclampsia
Folic Acid
Vitamin B Complex
Hematinics
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Hematologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014